FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022793562> ?p ?o ?g. }

• W2022793562 endingPage "e0123973" @default.
• W2022793562 startingPage "e0123973" @default.
• W2022793562 abstract "Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients.129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes.The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7%±7.6% vs. 64.6±6.4, p=0.019) and those with post-therapeutic recurrence (61.7±7.4 vs 64.3±6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (≦6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68±15.75 vs. 63.55±7.57, p=0.041).There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy." @default.
• W2022793562 created "2016-06-24" @default.
• W2022793562 creator A5016850615 @default.
• W2022793562 creator A5019385409 @default.
• W2022793562 creator A5022368844 @default.
• W2022793562 creator A5026991896 @default.
• W2022793562 creator A5053604127 @default.
• W2022793562 creator A5063993243 @default.
• W2022793562 creator A5073262667 @default.
• W2022793562 creator A5083858928 @default.
• W2022793562 creator A5087234106 @default.
• W2022793562 date "2015-04-28" @default.
• W2022793562 modified "2023-10-14" @default.
• W2022793562 title "LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy" @default.
• W2022793562 cites W1504303645 @default.
• W2022793562 cites W169270084 @default.
• W2022793562 cites W1967205042 @default.
• W2022793562 cites W1968170113 @default.
• W2022793562 cites W1968909284 @default.
• W2022793562 cites W1975163559 @default.
• W2022793562 cites W1975224807 @default.
• W2022793562 cites W1986937402 @default.
• W2022793562 cites W1997450107 @default.
• W2022793562 cites W1998116926 @default.
• W2022793562 cites W1998390679 @default.
• W2022793562 cites W1999318286 @default.
• W2022793562 cites W2006345816 @default.
• W2022793562 cites W2008124071 @default.
• W2022793562 cites W2011340279 @default.
• W2022793562 cites W2017127598 @default.
• W2022793562 cites W2028423120 @default.
• W2022793562 cites W2043363016 @default.
• W2022793562 cites W2046387526 @default.
• W2022793562 cites W2060345033 @default.
• W2022793562 cites W2061623083 @default.
• W2022793562 cites W2070164706 @default.
• W2022793562 cites W2072003049 @default.
• W2022793562 cites W2094390470 @default.
• W2022793562 cites W2095692554 @default.
• W2022793562 cites W2099359341 @default.
• W2022793562 cites W2099556709 @default.
• W2022793562 cites W2100957848 @default.
• W2022793562 cites W2102773999 @default.
• W2022793562 cites W2103114517 @default.
• W2022793562 cites W2103115795 @default.
• W2022793562 cites W2106401558 @default.
• W2022793562 cites W2106787323 @default.
• W2022793562 cites W2106993589 @default.
• W2022793562 cites W2115046713 @default.
• W2022793562 cites W2130383804 @default.
• W2022793562 cites W2141410747 @default.
• W2022793562 cites W2145678710 @default.
• W2022793562 cites W2150269898 @default.
• W2022793562 cites W2162933805 @default.
• W2022793562 cites W2171910021 @default.
• W2022793562 cites W4322703233 @default.
• W2022793562 cites W52121218 @default.
• W2022793562 doi "https://doi.org/10.1371/journal.pone.0123973" @default.
• W2022793562 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4412676" @default.
• W2022793562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25919688" @default.
• W2022793562 hasPublicationYear "2015" @default.
• W2022793562 type Work @default.
• W2022793562 sameAs 2022793562 @default.
• W2022793562 citedByCount "36" @default.
• W2022793562 countsByYear W20227935622015 @default.
• W2022793562 countsByYear W20227935622016 @default.
• W2022793562 countsByYear W20227935622017 @default.
• W2022793562 countsByYear W20227935622018 @default.
• W2022793562 countsByYear W20227935622019 @default.
• W2022793562 countsByYear W20227935622021 @default.
• W2022793562 countsByYear W20227935622022 @default.
• W2022793562 countsByYear W20227935622023 @default.
• W2022793562 crossrefType "journal-article" @default.
• W2022793562 hasAuthorship W2022793562A5016850615 @default.
• W2022793562 hasAuthorship W2022793562A5019385409 @default.
• W2022793562 hasAuthorship W2022793562A5022368844 @default.
• W2022793562 hasAuthorship W2022793562A5026991896 @default.
• W2022793562 hasAuthorship W2022793562A5053604127 @default.
• W2022793562 hasAuthorship W2022793562A5063993243 @default.
• W2022793562 hasAuthorship W2022793562A5073262667 @default.
• W2022793562 hasAuthorship W2022793562A5083858928 @default.
• W2022793562 hasAuthorship W2022793562A5087234106 @default.
• W2022793562 hasBestOaLocation W20227935621 @default.
• W2022793562 hasConcept C104317684 @default.
• W2022793562 hasConcept C121608353 @default.
• W2022793562 hasConcept C126322002 @default.
• W2022793562 hasConcept C143998085 @default.
• W2022793562 hasConcept C144301174 @default.
• W2022793562 hasConcept C146357865 @default.
• W2022793562 hasConcept C150194340 @default.
• W2022793562 hasConcept C151730666 @default.
• W2022793562 hasConcept C190727270 @default.
• W2022793562 hasConcept C2777982462 @default.
• W2022793562 hasConcept C2778260052 @default.
• W2022793562 hasConcept C2780962732 @default.
• W2022793562 hasConcept C33288867 @default.
• W2022793562 hasConcept C38180746 @default.
• W2022793562 hasConcept C526805850 @default.

• next